“Acute Myeloid Leukemia Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Myeloid Leukemia Market.
The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Acute Myeloid Leukemia Overview
Acute Myeloid Leukemia (AML) is a cancer affecting the bone marrow and blood. In AML, the bone marrow produces abnormal myeloid cells—immature white blood cells that should normally mature into red blood cells, white blood cells, and platelets. These abnormal cells proliferate uncontrollably, displacing healthy blood cells and impairing normal bone marrow function. This disruption results in a shortage of healthy blood cells and can cause a range of symptoms and complications. Common signs of AML include fatigue, weakness, shortness of breath, easy bruising or bleeding, frequent infections, fever, and weight loss, all stemming from the insufficient production of healthy blood cells and the accumulation of abnormal cells in the bone marrow and bloodstream. AML tends to progress rapidly, necessitating prompt medical diagnosis and intervention.
AML arises from genetic mutations in hematopoietic stem cells, which lead to the overproduction of immature myeloid precursor cells in the bone marrow. These abnormal cells fail to mature properly and accumulate, crowding out normal blood cells. This results in bone marrow failure and reduced production of red blood cells, white blood cells, and platelets. The presence of leukemic cells in the bloodstream causes systemic issues such as anemia, increased susceptibility to infections due to low neutrophil levels (neutropenia), and bleeding tendencies from low platelet counts (thrombocytopenia). Leukemic cells can also infiltrate other organs, such as the spleen, liver, and lymph nodes, leading to organ enlargement and additional complications.
The exact cause of AML is often unclear, but several risk factors have been identified. These include exposure to high levels of radiation, certain chemicals like benzene, prior chemotherapy or radiation for other cancers, genetic disorders such as Down syndrome, and smoking. In many cases, however, the precise cause of AML remains unknown.
Diagnosis of AML typically involves a comprehensive physical examination, blood tests to assess various blood cell levels and other markers, and a bone marrow biopsy to identify abnormalities in bone marrow cells. Treatment usually consists of chemotherapy to eradicate the abnormal cells and allow for the regeneration of healthy blood cells. Depending on the individual case, a bone marrow transplant may be recommended to replace the diseased marrow with healthy donor cells. Additional treatments, such as targeted therapy and immunotherapy, may also be employed based on the cancer’s specific characteristics and the patient’s overall health. Early detection and intervention are crucial for improving outcomes and enhancing the likelihood of long-term remission.
Recent advances in the Acute Myeloid Leukemia Pipeline Segment:
-
GlycoMimetics reports data from Phase III AML treatment trial: US-based biotechnology company GlycoMimetics has released topline results from its Phase III clinical trial of uproleselan, an E-selectin antagonist designed to treat relapsed/refractory acute myeloid leukaemia (r/r AML).
-
Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology
Acute Myeloid Leukemia Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Acute Myeloid Leukemia and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Myeloid Leukemia market.
Analysis of Emerging Therapies by Phases
Report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
-
Oral
-
Intravenous
-
Subcutaneous
Molecule Type
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as
-
Small molecule
-
Cell Therapy
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Myeloid Leukemia Therapeutic Segment @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
Acute Myeloid Leukaemia Emerging Drugs
Uproleselan: GlycoMimetics
GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of Acute Myeloid Leukemia (AML).
BST-236: BioSight
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Currently, the drug is in Phase II stage of its development for the treatment of Acute Myeloid Leukemia (AML).
MK-0482: Merck Sharp & Dohme LLC
MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. Currently, the drug is in Phase I stage of its development for the treatment of AML.
Ziftomenib – Kura Oncology
Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Currently, the drug is in Phase I/II stage of its development for the treatment of AML.
SENTI 202: Senti Biosciences
SENTI-202 is a first in class Logic-gated CAR-NK product engineered with an OR and a NOT Logic Gate gene circuit approach to enhance therapeutic efficacy and safety, with additional arming via expression of calibrated release IL-15 (crIL-15). A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in Preclinical stage of its development for the treatment of AML.
Leading Players in the Acute Myeloid Leukemia Therapeutics Market are Abbvie, Actinium Pharmaceuticals, Agastiya Biotech, AGC Biologics S.p.A., Agios Pharmaceuticals, Allogene therapeutics, Aprea Therapeutics, Aptevo Therapeutics, Armaceutica, Arog Pharmaceuticals, Astellas Pharma, Astex Pharmaceuticals, Inc., AstraZeneca, Bellicum Pharmaceuticals, BerGenBio ASA, Bio-Path Holdings, Biosight Ltd., Bristol-Myers Squibb, Cardiff Oncology, Celgene, CellCentric Ltd., Chimerix, Clear Creek Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Curis, Inc., Daiichi Sankyo., DCPrime BV, Delta-Fly Pharma, Forma Therapeutics, GEMoaB Monoclonals, Gilead Sciences, GlycoMimetics, GlycoMimetics Incorporated, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Immune-Onc Therapeutics, Immunicum, ImmunityBio, ImmunoGen, Inc., Immunomedics, Inc., Incyte Corporation, Janssen Research & Development, LLC, Jasper Therapeutics, Jazz Pharmaceuticals, Kronos Bio, MacroGenics, MediGene, Molecular Partners, New Epsilon Innovation Limited, NexImmune Inc., Novartis, Oncoceutics, Orca Bio, PersonGen BioTherapeutics, Pfizer, Poseida Therapeutics, Precigen, Inc., Rafael Pharmaceuticals Inc., Sellas Life Sciences Group, Sumitomo Dainippon Pharma Co., Ltd., Syndax Pharmaceuticals, Synimmune GmbH, Syros Pharmaceuticals, Takeda Oncology, TC BioPharm, Teva Pharmaceutical Industries, Xencor, Inc., and others.
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Acute Myeloid Leukemia Current Treatment Patterns
4. Acute Myeloid Leukemia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acute Myeloid Leukemia Late Stage Products (Phase-III)
7. Acute Myeloid Leukemia Mid-Stage Products (Phase-II)
8. Acute Myeloid Leukemia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Myeloid Leukemia Discontinued Products
13. Acute Myeloid Leukemia Product Profiles
14. Key Companies in the Acute Myeloid Leukemia Market
15. Key Products in the Acute Myeloid Leukemia Therapeutics Segment
16. Dormant and Discontinued Products
17. Acute Myeloid Leukemia Unmet Needs
18. Acute Myeloid Leukemia Future Perspectives
19. Acute Myeloid Leukemia Analyst Review
20. Appendix
21. Report Methodology
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/